Pharmacokinetics and safety of l-carnitine infused i. v. in healthy subjects

@article{Uematsu1988PharmacokineticsAS,
  title={Pharmacokinetics and safety of l-carnitine infused i. v. in healthy subjects},
  author={Toshihiko Uematsu and Toshiyuki Itaya and Masayoshi Nishimoto and Yoshiharu Takiguchi and Atsuhiro Mizuno and Mitsuyoshi Nakashima and Kumiko Yoshinobu and Terumitsu Hasebe},
  journal={European Journal of Clinical Pharmacology},
  year={1988},
  volume={34},
  pages={213-216}
}
SummaryThe pharmacokinetics and safety of a brief i. v. infusion of l-carnitine 0, 20, 40 and 60 mg/kg have been investigated in 10 healthy subjects.The diurnal intraindividual variability of plasma carnitine was small (C. V.=3.0, 3.9 and 3.9%, respectively), and the total 24 h excretion in urine was also small and relatively constant: 4.6, 21.5 and 13.0 mg/day in the controls vs 4.6, 20.2 and 6.0 mg/day during treatment in the three subjects to whom saline alone was administered according to a… CONTINUE READING
BETA

Similar Papers

Tables and Topics from this paper.

Explore Further: Topics Discussed in This Paper

References

Publications referenced by this paper.
SHOWING 1-10 OF 12 REFERENCES

Phar - macokinetics of 1carnitine in man following intravenous infusion of dlcarnitine

PG Welling, JH Thomsen, AL Shug, Tse FIN
  • Int J Clin Pharmacol Biopharm
  • 1979

Improved stress tolerance of the ischemic human Myocardium after administration of carnitine

TH Thomsen, AL Shug, +3 authors SL DeFelice
  • Am J Physiot
  • 1978
VIEW 1 EXCERPT

The metabolism consequences of the effects of carnitine on long chain fatty acid oxidation. In: Gran FC (ed) Cellular compartmentalization and control of fatty acid metabolism

IB Fritz
  • 1968
VIEW 1 EXCERPT

Camitine acyltransferase. II. Inhibition by carnitine analogue and by sulfhydryl reagents

IB Friz, SK Schultz
  • J Biol Chem
  • 1965
VIEW 1 EXCERPT